303 related articles for article (PubMed ID: 28851389)
1. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
[TBL] [Abstract][Full Text] [Related]
2. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
3. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
4. Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.
Hamada S; Urakawa H; Kozawa E; Futamura N; Ikuta K; Shimoyama Y; Nakamura S; Ishiguro N; Nishida Y
Tumour Biol; 2014 May; 35(5):4561-6. PubMed ID: 24390670
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
7. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
8. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
[TBL] [Abstract][Full Text] [Related]
9. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
Nishida Y; Tsukushi S; Urakawa H; Hamada S; Kozawa E; Ikuta K; Ando Y; Ishiguro N
Int J Clin Oncol; 2015 Dec; 20(6):1211-7. PubMed ID: 25899770
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used anti-beta-catenin antibodies.
Yamada Y; Hirata M; Sakamoto A; Noguchi T; Ito K; Nishida Y; Matsuda S; Haga H
Pathol Int; 2021 Jun; 71(6):392-399. PubMed ID: 33788979
[TBL] [Abstract][Full Text] [Related]
13. MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis.
Shimizu K; Hamada S; Sakai T; Ito S; Urakawa H; Arai E; Ikuta K; Koike H; Ishiguro N; Nishida Y
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):751-757. PubMed ID: 31448875
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis.
Takada N; Mussazhanova Z; Hirokawa M; Nakashima M; Miyauchi A
Pathobiology; 2018; 85(5-6):300-303. PubMed ID: 30223266
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
17. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
19. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
